Check patentability & draft patents in minutes with Patsnap Eureka AI!

Anti-H1N1 influenza virus hemagglutinin protein neutralizing monoclonal antibody ZJU11-01 and application thereof

A technology of monoclonal antibody and hemagglutinin protein, applied in antiviral immunoglobulin, chemical instruments and methods, biochemical equipment and methods, etc., can solve problems such as oseltamivir resistance and influenza virus resistance mutations

Pending Publication Date: 2022-04-15
THE FIRST AFFILIATED HOSPITAL ZHEJIANG UNIV COLLEGE OF MEDICINE
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] At present, the antiviral drugs for clinical treatment of influenza are mainly oseltamivir and amantadine, but studies have shown that the resistance rate of H1N1 influenza virus to amantadine has exceeded 90%
In addition, in clinical studies, it was found that influenza virus would develop drug-resistant mutations during drug exposure, resulting in resistance to oseltamivir

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-H1N1 influenza virus hemagglutinin protein neutralizing monoclonal antibody ZJU11-01 and application thereof
  • Anti-H1N1 influenza virus hemagglutinin protein neutralizing monoclonal antibody ZJU11-01 and application thereof
  • Anti-H1N1 influenza virus hemagglutinin protein neutralizing monoclonal antibody ZJU11-01 and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0057] Example 1. Preparation method of monoclonal antibody against H1N1 influenza virus hemagglutinin protein

[0058] (1) Immunization of mice: for the first immunization, the H1N1 influenza virus hemagglutinin whole protein and the adjuvant were uniformly mixed in equal volumes, and the total volume was 600 microliters. Each BALB / C mouse 0.1 ml (containing 30 micrograms of H1N1 influenza virus hemagglutinin whole protein antigen) was intramuscularly injected into the inner thigh. On the 21st day, a dose of booster immunization was given in the same way. On the 35th day, a small amount of tail blood was collected for enzyme-linked immunosorbent assay, and the antibody titer reached 1:128000. Immediately after that, a booster immunization was injected into the tail vein, and cell fusion was carried out 3 days later.

[0059] (2) Cultivation of mouse myeloma cell SP2 / 0: the SP2 / 0 myeloma cell line from BALB / C mouse was cultured and passaged in DMEM medium containing 10% bovin...

Embodiment 2

[0069] Example 2. Antiviral effect of monoclonal antibody ZJU11-01 against H1N1 influenza virus HA protein

[0070] (1) Microneutralization experiment: ① H1N1 influenza virus (A / Michigan / 45 / 2015) was titrated to half the infection dose of tissue cells; ② MDCK cells were inoculated in 96-well culture plates, 2×10 per well 4Cells were cultured in a 37°C incubator containing 5% carbon dioxide for 24 hours; ③Dilute the virus with virus culture solution containing 0.2% trypsin to 100 times half of the infectious dose of tissue cells per 50 microliters; ④In a 96-well culture plate 10 micrograms per milliliter of monoclonal antibody ZJU11-01 was diluted to different concentrations (1:1, 1:2, 1:4, 1:8, 1:16, 1:32, 1:16) with virus culture solution. 64, 1:128, 1:256, 1:521), 50 microliters per well; ⑤ Add 50 microliters of 100 times half the infectious dose of tissue cells per 50 microliters of virus solution to the wells with antibodies, and mix Evenly, do 4 duplicate holes for each ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a neutralizing monoclonal antibody ZJU11-01 of an anti-H1N1 influenza virus hemagglutinin protein and an application of the neutralizing monoclonal antibody ZJU11-01. The invention relates to an anti-H1N1 influenza virus hemagglutinin protein neutralizing monoclonal antibody ZJU11-01, the subtype of the monoclonal antibody is IgG1, kappa type, and the monoclonal antibody can be specifically combined with an H1N1 influenza virus hemagglutinin protein antigen. The heavy chain amino acid sequence of the antibody is shown as SEQ ID No.2, and the light chain amino acid sequence of the antibody is shown as SEQ ID No.4. The monoclonal antibody is subjected to further physical and chemical property analysis and functional identification, and the monoclonal antibody can effectively neutralize and treat H1N1 seasonal influenza virus infection. The invention provides an effective tool for treating H1N1 seasonal influenza virus infection, and can be popularized and applied.

Description

technical field [0001] The invention belongs to the field of biotechnology, and relates to the preparation and application of neutralizing monoclonal antibodies against H1N1 influenza virus hemagglutinin protein. It is a hybridoma that secretes monoclonal antibodies against hemagglutinin protein by using cell engineering and antibody engineering technologies. The cell line was induced ascites from mice of the same strain, and the monoclonal antibody ZJU11-01 against the hemagglutinin protein was prepared, which was identified as IgG1 and κ type, and then the application of the antibody was realized through affinity purification and other technologies. Background technique [0002] The hemagglutinin proteins on the surface of influenza A viruses are mainly divided into 18 subtypes, which are further divided into two phylogenetic groups: Group 1 (H1, H2, H5, H6, H8, H9, H11, H12, H13, H16 , H17 and H18 subtypes) and group 2 (H3, H4, H7, H10, H14 and H15 subtypes). Currently, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K16/10C07K1/22C12N5/20G01N33/577G01N33/569C12R1/91
Inventor 吴海波杨帆吴南屏姚航平
Owner THE FIRST AFFILIATED HOSPITAL ZHEJIANG UNIV COLLEGE OF MEDICINE
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com